FDA Feedback Rocks uniQure: Gene Therapy for Huntington’s Disease Delayed
UniQure's stock plummeted after the FDA unexpectedly decided that the current clinical trial data for its promising Huntington's disease therapy, AMT-130, is not adequate for immediate marketing application (BLA).